Financial Counselors Inc. Has $5.94 Million Stock Position in GSK plc (NYSE:GSK)

Financial Counselors Inc. reduced its stake in GSK plc (NYSE:GSK) by 2.1% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 145,175 shares of the pharmaceutical company’s stock after selling 3,055 shares during the quarter. Financial Counselors Inc.’s holdings in GSK were worth $5,935,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. FMR LLC boosted its position in shares of GSK by 8.3% during the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after buying an additional 2,224,345 shares during the last quarter. Fisher Asset Management LLC grew its holdings in shares of GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock valued at $759,425,000 after purchasing an additional 870,449 shares during the last quarter. Primecap Management Co. CA raised its holdings in GSK by 2.4% during the 3rd quarter. Primecap Management Co. CA now owns 14,853,755 shares of the pharmaceutical company’s stock valued at $607,222,000 after buying an additional 342,365 shares during the last quarter. Provident Trust Co. increased its position in shares of GSK by 1.7% during the third quarter. Provident Trust Co. now owns 3,953,602 shares of the pharmaceutical company’s stock valued at $161,623,000 after buying an additional 66,765 shares during the period. Finally, Equity Investment Corp grew its position in shares of GSK by 1.8% in the 3rd quarter. Equity Investment Corp now owns 3,496,254 shares of the pharmaceutical company’s stock worth $142,927,000 after buying an additional 63,052 shares during the period. 15.74% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts recently commented on GSK shares. Argus raised shares of GSK to a “strong-buy” rating in a research report on Wednesday, August 7th. Barclays raised GSK to a “hold” rating in a research note on Tuesday, August 27th. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Guggenheim cut shares of GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Jefferies Financial Group cut GSK from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating and three have issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Stock Up 0.9 %

Shares of NYSE GSK opened at $34.33 on Friday. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98. The firm has a market cap of $71.15 billion, a price-to-earnings ratio of 22.29, a PEG ratio of 1.31 and a beta of 0.66. GSK plc has a 52-week low of $32.83 and a 52-week high of $45.92. The business’s 50 day moving average is $37.42 and its two-hundred day moving average is $40.09.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, January 9th. Investors of record on Friday, November 15th will be given a $0.3928 dividend. The ex-dividend date of this dividend is Friday, November 15th. This is a boost from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 dividend on an annualized basis and a yield of 4.58%. GSK’s payout ratio is 99.35%.

Insiders Place Their Bets

In related news, major shareholder Plc Gsk acquired 2,791,930 shares of the firm’s stock in a transaction that occurred on Friday, September 27th. The shares were acquired at an average price of $8.00 per share, with a total value of $22,335,440.00. Following the completion of the purchase, the insider now directly owns 16,775,691 shares in the company, valued at approximately $134,205,528. The trade was a 19.97 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 10.00% of the stock is currently owned by insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.